Related Experiment Video

Updated: Jun 12, 2026

Three-Dimensional (3D) Tumor Spheroid Invasion Assay
12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer

Stephan Huveneers1, Erik H J Danen

  • 1Dynamics of Cell Adhesion, Hubrecht Institute and University Medical Centre Utrecht, The Netherlands. s.huveneers@hubrecht.eu

Thescientificworldjournal
|June 22, 2010
PubMed

Insights

The integrin beta3-c-Src interaction activates c-Src kinase, driving platelet aggregation and tumor growth. Disrupting this complex offers potential antithrombotic and anticancer therapies.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Oncology

Background:

  • Integrin adhesion signaling activates Src family kinases, crucial for cellular functions.
  • The alphaIIbbeta3 integrin directly interacts with c-Src kinase in platelets, promoting its activation via beta3 subunit clustering.
  • This interaction is implicated in both platelet aggregation and the oncogenic potential of c-Src in tumor cells.

Purpose of the Study:

  • To provide an overview of the beta3-c-Src interaction.
  • To discuss the implications of this interaction in platelet and tumor cell signaling.
  • To explore therapeutic strategies targeting the beta3-c-Src interaction.

Main Methods:

  • Literature review of studies on integrin-Src interactions.
  • Analysis of signaling pathways in platelets and tumor cells.
  • Discussion of existing and potential therapeutic interventions.

Main Results:

  • The beta3-c-Src interaction is a key signaling event in platelets, driving aggregation.
  • This complex promotes c-Src oncogenic activity and tumor growth in alphavbeta3-expressing cells.
  • Elevated c-Src activity and alphavbeta3 levels are common in human tumors, suggesting a role in progression.

Conclusions:

  • The beta3-c-Src signaling complex plays a significant role in platelet function and tumor progression.
  • Targeting the beta3-c-Src interaction presents a promising avenue for developing antithrombotic and anticancer therapies.

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...